title: The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer.
abstract: Background - aims: The long-term survival of pancreatic cancer is poor even after potentially curative resection. The incidence of local-regional failures is high. There is evidence that hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) is effective in controlling the local-regional failures. The purpose of the study is to identify the effect of HIPEC after surgical removal of pancreatic carcinoma. Patients - Methods: Prospective study including 33 patients with resectable pancreatic carcinomas. All patients underwent surgical resection (R0) and ΗIPEC as an adjuvant. Morbidity and hospital mortality were recorded. The patients were followed-up for 5 years. Survival was calculated. Recurrences and the sites of failure were recorded.
  
  
  
  The mean age of the patients was 67.8 ± 11.1 years (38-86). The hospital mortality was 6.1% (2 patients) and the morbidity 24.2% (8 patients). The overall 5-year survival was 24%. The mean and median survival was 33 and 13 months, respectively. The median follow-up time was 11 months. The recurrence rate was 60.6% (20 patients). Three patients were recorded with local-regional failures (9.1%) and the others with liver metastases.
  
  
  
  It appears that HIPEC as an adjuvant following potentially curative resection (R0) of pancreatic carcinoma may effectively control the local-regional disease. Prospective randomised studies are required.
authors.affiliation: a Department of Surgical Oncology , Metropolitan Hospital, Programme of Peritoneal Surface Malignancy , Athens , Greece.
authors.forename: Antonios-Apostolos
authors.initials: AA
authors.lastname: Tentes
authors.affiliation: a Department of Surgical Oncology , Metropolitan Hospital, Programme of Peritoneal Surface Malignancy , Athens , Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Stamou
authors.affiliation: a Department of Surgical Oncology , Metropolitan Hospital, Programme of Peritoneal Surface Malignancy , Athens , Greece.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Pallas
authors.affiliation: a Department of Surgical Oncology , Metropolitan Hospital, Programme of Peritoneal Surface Malignancy , Athens , Greece.
authors.forename: Christina
authors.initials: C
authors.lastname: Karamveri
authors.affiliation: b Department of Surgical Oncology , Euromedica Kyanous Stavros , Thessaloniki , Greece.
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Kyziridis
authors.affiliation: b Department of Surgical Oncology , Euromedica Kyanous Stavros , Thessaloniki , Greece.
authors.forename: Christos
authors.initials: C
authors.lastname: Hristakis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D006979:Hyperthermia, Induced; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010190:Pancreatic Neoplasms / Q000601:surgery* / Q000628:therapy*
keywords: HIPEC; Pancreatic cancer; recurrence; survival